BIB241220C35000
- 0.00
- 0.000.00%
Ultra Nasdaq Biotechnology Proshares Newsroom
AstraZeneca, Merck Report Positive Long-term Data for Lynparza
10 Health Care Stocks Whale Activity In Today's Session
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Demystifying Amgen: Insights From 13 Analyst Reviews
B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Amgen Analyst Ratings
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Gilead Sciences Analyst Ratings
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting
Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In...
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Vertex Reports Positive Long-term Data for Casgevy